These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9013374)

  • 21. Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects.
    Zheng T; Su CH; Zhao J; Zhang XJ; Zhang TY; Zhang LR; Kan QC; Zhang SJ
    Pharmazie; 2013 Apr; 68(4):257-60. PubMed ID: 23700791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of epigallocatechin gallate on the bioavailability and pharmacokinetics of diltiazem in rats.
    Li C; Choi JS
    Pharmazie; 2008 Nov; 63(11):815-8. PubMed ID: 19069242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects.
    Dingemanse J; Nicolas L
    Clin Drug Investig; 2013 Mar; 33(3):207-13. PubMed ID: 23381958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype.
    Molden E; Johansen PW; Bøe GH; Bergan S; Christensen H; Rugstad HE; Rootwelt H; Reubsaet L; Lehne G
    Clin Pharmacol Ther; 2002 Sep; 72(3):333-42. PubMed ID: 12235455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gender related pharmacokinetics of diltiazem in healthy subjects.
    Sáenz-Campos D; Bayés MC; Martin S; Barbanoj MJ; Jané F
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):397-400. PubMed ID: 7582396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of moricizine HCl.
    Woosley RL; Morganroth J; Fogoros RN; McMahon FG; Humphries JO; Mason DT; Williams RL
    Am J Cardiol; 1987 Oct; 60(11):35F-39F. PubMed ID: 3310583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative bioavailability of Cardizem CD and Tiazac controlled-release diltiazem dosage forms after single and multiple dosing in healthy volunteers.
    Dimmitt DC; Bhargava VO; Arumugham T; Eller M; Weir SJ
    Am J Ther; 1998 May; 5(3):173-9. PubMed ID: 10099056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose proportionality of moricizine after escalating multiple doses in healthy volunteers.
    Benedek IH; Garner DM; Pieniaszek HJ
    J Clin Pharmacol; 1991 Mar; 31(3):229-32. PubMed ID: 2019664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steady-state pharmacokinetics of high-dose diltiazem hydrochloride (Cardizem CD) administered once daily in healthy volunteers.
    Robbins-Weilert DK; Giesing DH; Weir SJ
    Am J Ther; 1999 Jul; 6(4):211-6. PubMed ID: 11329099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The kinetic profiles of amlodipine and of a sustained release form of diltiazem.
    Fourtillan JB; Ingrand I; Decourt JP; Istin B; Girault J
    Therapie; 1998; 53(2):121-6. PubMed ID: 9773111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.
    Glesby MJ; Aberg JA; Kendall MA; Fichtenbaum CJ; Hafner R; Hall S; Grosskopf N; Zolopa AR; Gerber JG;
    Clin Pharmacol Ther; 2005 Aug; 78(2):143-53. PubMed ID: 16084849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Further elucidation of pharmacokinetic interaction between diltiazem and warfarin.
    Stoysich AM; Lucas BD; Mohiuddin SM; Hilleman DE
    Int J Clin Pharmacol Ther; 1996 Feb; 34(2):56-60. PubMed ID: 8929747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of moricizine in young patients.
    Rice PJ; LeClair IO; Stone WL; Mehta AV
    J Clin Pharmacol; 1995 Oct; 35(10):1016-9. PubMed ID: 8568009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit.
    Homsy W; Caillé G; du Souich P
    Pharm Res; 1995 Nov; 12(11):1722-6. PubMed ID: 8592676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The interaction of the diltiazem with oral and intravenous cyclosporine in rats.
    Kalkan S; Gumustekin M; Aygoren O; Tuncok Y; Gelal A; Guven H
    Eur J Drug Metab Pharmacokinet; 2004; 29(2):119-23. PubMed ID: 15230340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension.
    Watanabe H; Kosuge K; Nishio S; Yamada H; Uchida S; Satoh H; Hayashi H; Ishizaki T; Ohashi K
    Life Sci; 2004 Dec; 76(3):281-92. PubMed ID: 15531380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The interaction of diltiazem with lovastatin and pravastatin.
    Azie NE; Brater DC; Becker PA; Jones DR; Hall SD
    Clin Pharmacol Ther; 1998 Oct; 64(4):369-77. PubMed ID: 9797793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses.
    Schwarzwald CC; Sams RA; Bonagura JD
    J Vet Pharmacol Ther; 2006 Jun; 29(3):165-71. PubMed ID: 16669860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of morin pretreatment on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem in rats.
    Choi HJ; Choi JS
    Arch Pharm Res; 2005 Aug; 28(8):970-6. PubMed ID: 16178425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers.
    Da Ros L; Squassante L; Milleri S
    Clin Pharmacokinet; 2003; 42(1):99-106. PubMed ID: 12489980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.